ATRAAtara Biotherapeutics, Inc.
The schedule
- Thu15Oct
Required corporate action to fund ongoing ATA3219 trials, likely taking the form of a secondary offering, ATM utilization, or a definitive strategic transaction.
- Thu3Dec
Critical clinical readout for Atara's flagship allogeneic CD19 CAR-T candidate, ATA3219, presented at the American Society of Hematology annual meeting.
- Mon8Feb
- Sun9May
Full-year 2026 financial wrap-up, focusing on Pierre Fabre milestone realizations and updated trial initiation timelines for the broader autoimmune pipeline.
- Tue11May
Past
- Thu1Oct
Actual outcome: Bull · $9.61 at outcome
ATRA experienced a significant positive move likely due to a favorable clinical trial readout, which signaled strong efficacy or safety data. The results could have demonstrated improved outcomes or met key endpoints, leading to increased investor confidence and a sharp upward re-rating. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +13.1% from 2026-10-01 to 2026-10-02 (~2.9σ vs typical 1d vol). Target evaluation date 2026-10-06 (not yet reached as of 2026-10-02). Confidence 95%.
ATRA experienced a significant positive move likely due to a favorable clinical trial readout, which signaled strong efficacy or safety data. The results could have demonstrated improved outcomes or met key endpoints, leading to increased investor confidence and a sharp upward re-rating. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +13.1% from 2026-10-01 to 2026-10-02 (~2.9σ vs typical 1d vol). Target evaluation date 2026-10-06 (not yet reached as of 2026-10-02). Confidence 95%.
- Thu13Aug
Actual outcome: Mixed · $5.24 at outcome
ATRA reported Q2 EPS of -$0.25, exactly meeting analyst estimates. The stock initially fell 19.4% as the in-line print failed to immediately alleviate concerns over the company's critically low cash position and ongoing burn rate. However, shares subsequently rebounded to $9.80 by late May, suggesting the strategic runway update ultimately provided enough clarity for the market to stabilize.
ATRA reported Q2 EPS of -$0.25, exactly meeting analyst estimates. The stock initially fell 19.4% as the in-line print failed to immediately alleviate concerns over the company's critically low cash position and ongoing burn rate. However, shares subsequently rebounded to $9.80 by late May, suggesting the strategic runway update ultimately provided enough clarity for the market to stabilize.
- Tue12May
Actual outcome: Bull · $10.07 at outcome
Price reached or exceeded bull target ($11.50) at outcome date.
Q1 2026 earnings will update the market on how quickly Atara is burning cash post-portfolio restructuring, any additional licensing revenue, and whether management can credibly outline a cash runway through key ATA3219 milestones. With the stock at $8.34 and trading rich versus current revenues, confirmation of disciplined spend and visibility to at least late-2027 could justify a move toward $11.50, while a higher-than-expected burn rate or vague runway commentary could push shares back toward $11.50 as investors re-price dilution risk.